21 March, 2020

NEWS – A Message from Ergomed plc Executive Chairman Dr Miroslav Reljanovic : Ergomed Response to COVID-19

Dear Valued Clients, Partners and Industry Colleagues,

Ergomed plc shares its ardent compassion with the communities impacted worldwide by COVID-19. As the world responds to this pandemic, we remain committed to supporting you to ensure that the vital delivery of our work continues.

I’m writing to explain the necessary steps we are taking to protect the health and safety of our employees and their families, our customers, patients and communities. I also want to assure you that we are flexible and continually adapting to navigate this global health crisis. Our clinical research team is actively at the forefront of supporting potential effective therapy in the treatment of COVID-19.

The work they are doing is fully aligned with the company’s duty of care to society for pharmacovigilance as well as clinical research and it is truly impactful. We appreciate all the efforts being made across the company by all our staff in these challenging times.

As part of the continuous risk management process, Ergomed plc leadership team is evaluating regularly the potential impact of the outbreak on the business continuity, in particular planning and execution of clinical studies and pharmacovigilance support.

Health, safety & non-essential travel

The safety of our staff is our utmost priority. We have taken a number of measures aimed at protecting the welfare of our employees, and to minimize the risk of spreading the virus within our global office network.

Currently, more than 80% of our employees are working remotely with robust technologies in place, to ensure the safety of our staff as much as possible while effectively providing our services.

All non-business critical travel has been restricted – and we have enabled platforms to bridge our teams.

With evolving travel restrictions, our leadership is following governmental restrictions and evaluating all meetings to make cautious decisions to optimize virtual connections.

The Executive and Management Teams are meeting daily to discuss our Business Continuity Plan priorities.

Our business continuity and virtual work

The actions we are taking follow the advice from the WHO, the respective government guidance and health authorities.

We have considered several mitigation strategies, which may be implemented on a study by study basis, to ensure that we maintain appropriate oversight over the study conduct, patient safety and data integrity at all times.

We have provided options for remote monitoring in high-impact/restricted regions, and we have the ability to implement our remote monitoring as needed. Teams will be in direct contact with you to recommend the appropriate individual deployment strategy as needed.

All Ergomed plc Project Managers are performing a risk assessment for their studies to evaluate the potential impact on study deliverables and they are preparing study-specific strategies which will be shared with you during the following days.

Each pharmacovigilance Project Director working within our specialised PrimeVigilance business is conducting an impact analysis on their projects, to determine if additional measures are needed.

I am proud of the Ergomed Leaders who are facilitating new ways of working and collaborating under these challenging times. On behalf of Ergomed Plc, we value our relationship with you, the shared impact we can make for patients and their safety, and we are committed to providing the highest quality service.

Should you have specific questions, please reach out to your Ergomed plc business contact or via our regularly updated website (www.ergomedplc.com).

If there are significant changes to the approach we have taken, we will inform you as appropriate.

Thank you for your continued support.

Warm regards,

Miroslav Reljanovic
Executive Chairman
Ergomed plc

About Ergomed plc
Ergomed provides specialist services to the pharmaceutical industry spanning all phases of clinical trials, post-approval pharmacovigilance and medical information. Ergomed’s fast-growing, profitable services business includes a full range of high-quality contract research and trial management (CRO) services under the Ergomed brand together with an industry-leading suite of specialist pharmacovigilance (PV) solutions, integrated under the PrimeVigilance brand, and an internationally recognized specialist expertise in orphan drug development, under the PSR brand. To learn more about our worldwide specialist full-service CRO, visit: http://ergomedplc.com.

This site uses cookies to personalise and customise your experience. By clicking “I Accept", you consent to cookies in accordance with our privacy policy.

Privacy Settings saved!
Privacy Settings

When you visit any web site, it may store or retrieve information on your browser, mostly in the form of cookies. Control your personal Cookie Services here.

These cookies are necessary for the website to function and cannot be switched off in our systems.

In order to use this website we use the following technically required cookies
  • wordpress_test_cookie
  • wordpress_logged_in_
  • wordpress_sec

In order to use this website we use the following technically required cookies
  • __cfduid

Decline all Services
Accept all Services